Pfizer To Revert To ‘Business As Normal’ After Pricing Increase Pause, CEO Says On Earnings Call

The pharmaceutical giant signaled that prescription drug price increases could return in 2019 after postponing planned hikes in July. The news was made during Pfizer's third-quarter earnings call, in which the drugmaker also said its profits were up but that revenue did not hit forecasts. Bloomberg also reports on the company's hospital drug problems.

from Kaiser Health News https://ift.tt/2Pz05MV